Skip to main content
Equibles
SMMT logo

SMMT · Summit Therapeutics Inc. · Webcasts, Transcripts & Audio

Track SMMT — free

Use SMMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.15 -0.93 (-6.14%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Going-concern doubt — cleared Nov 4, 2026

The latest filing no longer states the doubt (first flagged Jul 23, 2026).

View the 10-Q filed Nov 4, 2026
Market Cap
$11.32B
Shares
799.76M
Volume · Nov 13 5.56M Avg daily vol (3M) 6.24M

Summit Therapeutics Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Summit Therapeutics Inc. (SMMT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)

Embed Summit Therapeutics Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview
                
            

        

        
    

    




    


    
    

        

            
            
            
            
        

            

                
                    
                    
                    
                    
                    
            

        
        
    


    
    

            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q3

                    
2026-11-04

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q3 2026 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.26

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q2

                    
2026-07-23

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                HARMONY trial updated OS analysis
                                HARMONY 3 and HARMONY 6 NSCLC trials
                                Commercial uptake in China
                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.28

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-06-08

                


                
                

                    
Summit Therapeutics Inc. (SMMT) June 8, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q1

                    
2026-06-01

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q1 2026 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.24

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q4

                    
2026-02-23

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Ivonescimab data readouts and approvals
                                FDA BLA review and HARMONi regulatory path
                                HARMONi-3 trial progress and interim analysis
                    

                


                
                

                        Results not yet reported
                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q3

                    
2025-10-20

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                BLA submission for ivonescimab
                                HARMONi-6 Phase III data in squamous NSCLC
                                HARMONi-3 independent histologies and filing strategy
                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.31

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q1

                    
2025-05-01

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                HARMONi global Phase III trial readout
                                Ivonescimab clinical progress and regulatory milestones
                                Partnership with Akeso
                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.09

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q4

                    
2025-02-24

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Harmony 3 amendment and patient population expansion
                                Pfizer ADC collaboration
                                Harmony 7 monotherapy vs pembrolizumab trial
                    

                


                
                

                        Results not yet reported
                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q3

                    
2024-10-30

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                HARMONi-3 amendment to include non-squamous NSCLC
                                HARMONi EGFR-mutant Phase 3 enrollment and timeline
                                HARMONi-2 ivonescimab vs pembro data
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0

                                

                                

                                    
Diluted EPS

                                    
$-0.08

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q2

                    
2024-08-06

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.09

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q1

                    
2024-05-01

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Ivonescimab clinical development and mechanism
                                HARMONi and HARMONi-3 registrational trials
                                Akeso partnership and HARMONi-A data
                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.06

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q4

                    
2024-02-20

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Ivonescimab lead asset progress
                                Unmet need in lung cancer
                                Akeso partnership and global trials
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0*

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q3

                    
2023-11-07

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q3 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0

▼ 100% YoY                                

                                

                                    
Diluted EPS

                                    
$-0.03

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q2

                    
2023-08-09

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q2 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0

▼ 100% YoY                                

                                

                                    
Diluted EPS

                                    
$-0.02

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q1

                    
2023-05-11

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q1 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0

▼ 100% YoY                                

                                

                                    
Diluted EPS

                                    
$-1.43

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY22 · Q4

                    
2023-03-09

                


                
                

                    
Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0*

▼ 100% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
    

    

        
Showing 1–16 of 16 webcasts

    

    

    
    


        

    

        

            

                Key facts
                    
                        CIK
                        1599298
                    
                    
                        CUSIP
                        86627T108
                    
                    
                        13F (30d)
                        218 filings
                        203 filers
                    
                    
                    
                         Visit website
                        
                    
                    
                         Investor relations